FDA approves first tumour-infiltrating lymphocyte (TIL) therapy, bolstering hopes for cell therapies in solid cancers
Asher Mullard
Topics & Concepts
Tumor-infiltrating lymphocytesSolid tumorLymphocyteMedicineCancer researchImmunologyPathologyOncologyImmunotherapyCancerImmune systemInternal medicineCAR-T cell therapy researchCancer Genomics and DiagnosticsCancer Immunotherapy and Biomarkers